Ark Biosciences of Shanghai In-Licenses RSV Treatment from Roche

Ark Biosciences, an innovative Shanghai biotech startup, has in-licensed rights to Roche's Respiratory Syncytial Virus (RSV) drug candidate, AK0529. Pre-clinical work on AK0529 has been completed. Ark will receive all of Roche’s data documentation for the drug along with its API. Roche will receive an upfront payment, milestones and royalties. Ark, which will manufacture the product, owns global rights to AK0529, including the right to sub-license. More details.... Stock Symbol: (VX: ROG) Share this with colleagues: // //